Pazopanib is an oral tyrosine kinase inhibitor registered for metastatic renal cell carcinoma and soft tissue sarcoma. Liver toxicity is a common side effect for this class of agents. | A remarkable response to pazopanib despite recurrent liver toxicity in a patient with a high grade endometrial stromal sarcoma a case report